Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. XBIO
stocks logo

XBIO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
639.16K
-12.3%
--
--
629.65K
+2.53%
--
--
690.12K
+6.26%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Xenetic Biosciences, Inc. (XBIO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -17.27%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-17.27%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Xenetic Biosciences Inc (XBIO.O) is -0.85, compared to its 5-year average forward P/E of -2.92. For a more detailed relative valuation and DCF analysis to assess Xenetic Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.92
Current PE
-0.85
Overvalued PE
-1.21
Undervalued PE
-4.63

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.04
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.10
Undervalued EV/EBITDA
-1.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
8.63
Current PS
0.00
Overvalued PS
18.14
Undervalued PS
-0.88
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

XBIO News & Events

Events Timeline

(ET)
2025-11-13
08:48:13
Xenetic Announces Q3 Earnings Per Share of 33 Cents, Up from 28 Cents Last Year
select
2025-10-10 (ET)
2025-10-10
09:38:09
Xenetic Sets Price for 735,000 Share Spot Secondary at $6.12
select
2025-08-13 (ET)
2025-08-13
08:39:59
Xenetic reports Q2 EPS (45c) vs. (83c) last year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
10-08TipRanks
What’s Driving the Rise of Pharmaceutical Stocks XBIO, UPC, XTLB, and ACXP Today?

  • Pharmaceutical Stock Movements: Several pharmaceutical stocks, including Xenetic Biosciences, Universe Pharmaceuticals, XTL Biopharmaceuticals, and Acurx Pharmaceuticals, saw significant pre-market gains despite no clear news or announcements explaining the rise.

  • Speculative Trading Influence: The surge in these stocks may be linked to speculative trading following a massive rally in Galecto shares, which spiked without news and then fell, indicating that retail traders are shifting their focus to other stocks for potential gains.

[object Object]
Preview
9.5
08-13NASDAQ.COM
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates

  • Earnings Performance: Xenetic Biosciences reported a quarterly loss of $0.45 per share, better than the expected loss of $0.64, marking a 29.69% earnings surprise; however, revenues of $0.59 million fell short of estimates by 7.81%.

  • Market Outlook: The company's stock has underperformed with a 30.8% decline this year, and its future performance will depend on management's commentary and revisions to earnings estimates, currently rated as Zacks Rank #3 (Hold).

[object Object]
Preview
9.0
03-13Business Insider
Xenetic presents preclinical data on DNase I with CAR T cells in murine model

  • Research Findings: Xenetic Biosciences presented preclinical data showing that co-administration of deoxyribonuclease I (DNase I) with CAR T cells significantly suppressed lung metastasis in a murine melanoma model, enhancing tumor control and survival compared to CAR T cell therapy alone.

  • Immune Response Improvement: The combination treatment led to increased infiltration of T and CAR T cells in tumors and reduced markers of T cell exhaustion, indicating that DNase I helps counteract the immunosuppressive environment of tumors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Xenetic Biosciences Inc (XBIO) stock price today?

The current price of XBIO is 2.54 USD — it has increased 4.96 % in the last trading day.

arrow icon

What is Xenetic Biosciences Inc (XBIO)'s business?

Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immuno-oncology technologies addressing difficult to treat cancers. The Company's Deoxyribonuclease (DNase) technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. It is focused on advancing the development of its DNase technology toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the currently available therapeutic options.

arrow icon

What is the price predicton of XBIO Stock?

Wall Street analysts forecast XBIO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for XBIO is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Xenetic Biosciences Inc (XBIO)'s revenue for the last quarter?

Xenetic Biosciences Inc revenue for the last quarter amounts to 1.03M USD, increased 67.19 % YoY.

arrow icon

What is Xenetic Biosciences Inc (XBIO)'s earnings per share (EPS) for the last quarter?

Xenetic Biosciences Inc. EPS for the last quarter amounts to -0.33 USD, increased 17.86 % YoY.

arrow icon

What changes have occurred in the market's expectations for Xenetic Biosciences Inc (XBIO)'s fundamentals?

The market is revising No Change the revenue expectations for Xenetic Biosciences, Inc. (XBIO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -17.27%.
arrow icon

How many employees does Xenetic Biosciences Inc (XBIO). have?

Xenetic Biosciences Inc (XBIO) has 2 emplpoyees as of December 05 2025.

arrow icon

What is Xenetic Biosciences Inc (XBIO) market cap?

Today XBIO has the market capitalization of 5.82M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free